Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG is a biotechnology company focused on gene editing and the development of gene-based medicines for serious human diseases. Its core technology is the CRISPR/Cas9 platform, which is designed to make precise changes to genomic DNA. The company is advancing a pipeline across several therapeutic areas, including hemoglobinopathies, CAR T cell therapies, in vivo gene editing, and type 1 diabetes. Its lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy developed for patients with transfusion-dependent beta-thalassemia, severe sickle cell disease, and related hemoglobin disorders. The pipeline also includes CAR T programs such as CTX112 and CTX131, in vivo candidates CTX310 and CTX320, and CTX211 for type 1 diabetes. CRISPR Therapeutics has strategic partnerships with Vertex Pharmaceuticals and is headquartered in Zug, Switzerland.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CRSP
|
$39.67
|
-17.7% Downside
|
Fair
|
$86.21
|
78.8% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-8.4x
|
2.6x
|
1,160.5x
|
4.628 B
|
3.108 B
|
14.5%
|
99.6%
|
7.1
|
—
|
70.6%
|
